Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
HERAN-Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Danish Lung Cancer Group
151 participants
Nov 22, 2018
INTERVENTIONAL
Summary
The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting seven weeks of intensive treatment. The aim is to study the efficiency as well as the safety of a new treatment option of heterogeneously hypofractionated radiotherapy for patients with locally advanced NSCLC who are not candidates for standard, high-dose chemoradiotherapy, either due to excessive irradiation of normal tissue (defined as category A patients) or due to fragility of the patient (category B patients).
Eligibility
Inclusion Criteria6
- Histologically or cytological confirmed locally advanced, inoperable NSCLC.
- Age ≥18 years.
- Signed informed consent.
- Performance status 0-2.
- Able to comply with study and follow-up procedures.
- Fertile women must have a negative pregnancy test. Fertile men and women must use effective contraception. Fertile women included in the study must use the pill, spiral, depot injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch for the duration of study treatment and one month thereafter.
Exclusion Criteria4
- Prior radiotherapy to the thorax, unless there is no significant overlap of current treatment volumes with previous treatment fields.
- Dose plan conforming to protocol planning criteria not possible.
- Uncontrolled metastatic disease.
- Other active malignant disease.
Interventions
A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03742687